Seegene has launched the Global Million Clinical Study (GMCS), an international initiative designed to evaluate the clinical utility of comprehensive syndromic PCR testing using real-world data from approximately one million clinical test cases.
The study will begin in South Korea and expand to healthcare institutions worldwide to collect large-scale testing data and assess disease-specific testing approaches for major infectious diseases. According to Seegene, the goal is to generate scientific evidence that could help inform future global testing standards and support more comprehensive diagnostic strategies.
Evaluating syndromic PCR in real-world settings
Unlike conventional targeted testing approaches that focus on individual pathogens, syndromic PCR testing can detect multiple potential causative pathogens in a single test. Through GMCS, Seegene plans to analyze real-world testing data that may reveal additional insights, including previously undetected pathogens, co-infections, pathogen genotypes, and regional and seasonal infection patterns.
The study will initially focus on three major infectious disease categories: reproductive tract infections, respiratory tract infections, and gastrointestinal tract infections. Seegene said the initiative aims to evaluate whether broader pathogen detection capabilities may provide additional information to support clinical decision-making beyond current testing approaches.
To support data analysis, Seegene will provide STAgora™, a real-time testing data analytics platform designed to analyze pathogen prevalence and infection trends across disease types and geographic regions.
Building evidence for future diagnostic standards
The company noted that although advanced PCR technologies can provide consistent diagnostic capabilities, testing practices differ across countries due to variations in clinical guidelines, healthcare systems, and reimbursement policies. As a result, patients with similar conditions may have access to different testing strategies depending on where they receive care.
Through GMCS, Seegene aims to build a scientific evidence base that reflects real-world clinical needs and supports the development of future testing standards.
“GMCS goes beyond simply accumulating real-world testing data,” said Jong-Yoon Chun, PhD, CEO & Founder of Seegene, in a press release. “It is the industry's first global clinical study of this scale, designed to compile scientific evidence to help open a new paradigm in diagnostics.”
“Innovation at Seegene does not end with developing advanced technologies,” Chun added. “Our goal is to translate advanced technology into new testing strategies in the global healthcare environment. By continuously accumulating scientific evidence, we hope to bring better diagnostic options for patients.”
Seegene emphasized that GMCS is an evidence-generation initiative and does not constitute medical advice, diagnostic guidance, or a product-specific performance claim.
Note: This news summary was generated by AI based on a published press release, followed by a review from human editors.
